1-8 of 8
btk inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL

Burcu Aslan, Gorkem Kismali, Lisa S. Chen, LaKesla R. Iles, Mikhila Mahendra, Michael Peoples, Mihai Gagea, Natalie W. Fowlkes, Xiaofeng Zheng, Jing Wang, Christopher P. Vellano, Joseph R. Marszalek, Maria Teresa Sabrina Bertilaccio, Varsha Gandhi
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3134–3146.
https://doi.org/10.1182/bloodadvances.2020003821
Published: 2021
Includes: Supplemental data
Journal Articles

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, David Simpson, Gavin Cull, Javier Munoz, Tycel J. Phillips, Won Seog Kim, Simon Rule, Siminder Kaur Atwal, Rachel Wei, William Novotny, Jane Huang, Michael Wang, Judith Trotman
Journal: Blood Advances
Blood Adv (2021) 5 (12): 2577–2585.
https://doi.org/10.1182/bloodadvances.2020004074
Published: 2021
Includes: Supplemental data
Journal Articles

Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects

H. Yesid Estupiñán, Thibault Bouderlique, Chenfei He, Anna Berglöf, Dhanu Gupta, Osama Saher, Miguel Ángel Daza Cruz, Lucia Peña-Perez, Liang Yu, Rula Zain, Mikael C. I. Karlsson, Robert Månsson, C. I. Edvard Smith
Journal: Blood Advances
Blood Adv (2020) 4 (11): 2439–2450.
https://doi.org/10.1182/bloodadvances.2019001319
Published: 2020
Includes: Supplemental data
Journal Articles

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

Clinical Trials & Observations
Christine E. Ryan, Matthew P. Cheng, Nicolas C. Issa, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1458–1463.
https://doi.org/10.1182/bloodadvances.2020001678
Published: 2020
Journal Articles

Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv . 2019;3(23):4021-4033.

Journal: Blood Advances
Blood Adv (2020) 4 (1): 112.
https://doi.org/10.1182/bloodadvances.2019001362
Published: 2020
Journal Articles

Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Luise Goldmann, Rundan Duan, Thorsten Kragh, Georg Wittmann, Christian Weber, Reinhard Lorenz, Philipp von Hundelshausen, Michael Spannagl, Wolfgang Siess
Journal: Blood Advances
Blood Adv (2019) 3 (23): 4021–4033.
https://doi.org/10.1182/bloodadvances.2019000617
Published: 2019
Includes: Supplemental data
Journal Articles

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Clinical Trials & Observations
Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1553–1562.
https://doi.org/10.1182/bloodadvances.2018030007
Published: 2019
Journal Articles

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

Clinical Trials & Observations
Zachary R. Hunter, Lian Xu, Nickolas Tsakmaklis, Maria G. Demos, Amanda Kofides, Cristina Jimenez, Gloria G. Chan, Jiaji Chen, Xia Liu, Manit Munshi, Joshua Gustine, Kirsten Meid, Christopher J. Patterson, Guang Yang, Toni Dubeau, Mehmet K. Samur, Jorge J. Castillo, Kenneth C. Anderson, Nikhil C. Munshi, Steven P. Treon
Journal: Blood Advances
Blood Adv (2018) 2 (21): 2937–2946.
https://doi.org/10.1182/bloodadvances.2018022962
Published: 2018
Includes: Supplemental data